AI Article Synopsis
- Recent developments in gastroenterology include improving colonoscopy quality through artificial intelligence.
- Ozanimod is being explored as a potential treatment for refractory ulcerative colitis, pending validation from Swissmedic.
- New insights into gastro-related issues include Rivaroxaban's higher risk of GI bleeding, revised classifications for esophageal disorders, and promising results from Semaglutide for metabolic steatosis.
Article Abstract
Among the recent advances in gastroenterology, colonoscopy with artificial intelligence is associated with a better quality of screening. In refractory UC, Ozanimod seems to be an interesting salvage treatment, which still needs to be validated by Swissmedic. Among the direct-acting anticoagulants, Rivaroxaban is more frequently associated with GI bleeding. The classification of oesophageal motor disorders has been recently revised, the Chicago v4.0 classification should be applied in diagnostic management. The use of Semaglutide seems to show very promising results in the management of metabolic steatosis. SARS-CoV-2 infection can be complicated by biliary tract disease, which can progress to hepatocellular failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2022.18.764-65.31 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!